Zenbexus: BMS earns first FDA approval for CELMoD class in multiple myeloma on August 14, 2026 Approved Burning Mouth Syndrome CELMoD Clinical Trials Darzalex dexamethasone iberdomide In complete remission MRD-negative Multiple Myeloma Neoplasm, Residual United States Food and Drug Administration Zenbexus +
FDA Approves GSK's Blenrep for Multiple Myeloma Treatment, Marking a Market Return on October 24, 2025 Approved Blenrep bortezomib dexamethasone Multiple Myeloma SmithKline Beecham United States Food and Drug Administration +
UK approval brings GSK's Blenrep back from the brink on April 18, 2025 Antibody-Drug Conjugates Approved Blenrep Cessation of life dexamethasone DREAMM-8 Multiple Myeloma Risk UK +